Your browser doesn't support javascript.
loading
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Ewing, Ailith; Meynert, Alison; Churchman, Michael; Grimes, Graeme R; Hollis, Robert L; Herrington, C Simon; Rye, Tzyvia; Bartos, Clare; Croy, Ian; Ferguson, Michelle; Lennie, Mairi; McGoldrick, Trevor; McPhail, Neil; Siddiqui, Nadeem; Dowson, Suzanne; Glasspool, Rosalind; Mackean, Melanie; Nussey, Fiona; McDade, Brian; Ennis, Darren; McMahon, Lynn; Matakidou, Athena; Dougherty, Brian; March, Ruth; Barrett, J Carl; McNeish, Iain A; Biankin, Andrew V; Roxburgh, Patricia; Gourley, Charlie; Semple, Colin A.
Afiliação
  • Ewing A; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom. ailith.ewing@igmm.ed.ac.uk.
  • Meynert A; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Churchman M; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Grimes GR; MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Hollis RL; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Herrington CS; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Rye T; Edinburgh Pathology, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Bartos C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Croy I; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Ferguson M; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
  • Lennie M; Department of Oncology, Ninewells Hospital, NHS Tayside, Dundee, Scotland, United Kingdom.
  • McGoldrick T; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom.
  • McPhail N; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom.
  • Siddiqui N; Department of Oncology, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom.
  • Dowson S; Institute of Education for Medical and Dental Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
  • Glasspool R; Department of Oncology, Raigmore Hospital, NHS Highland, Inverness, Scotland, United Kingdom.
  • Mackean M; Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.
  • Nussey F; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
  • McDade B; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, Scotland, United Kingdom.
  • Ennis D; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, Scotland, United Kingdom.
  • McMahon L; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, Scotland, United Kingdom.
  • Matakidou A; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
  • Dougherty B; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
  • March R; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, England, United Kingdom.
  • Barrett JC; Precision Medicine Scotland (PMS-IC), Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom.
  • McNeish IA; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, England, United Kingdom.
  • Biankin AV; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.
  • Roxburgh P; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
  • Gourley C; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
  • Semple CA; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, Scotland, United Kingdom.
Clin Cancer Res ; 27(11): 3201-3214, 2021 06 01.
Article em En | MEDLINE | ID: mdl-33741650
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / Proteína BRCA1 / Proteína BRCA2 / Reparo de DNA por Recombinação / Recombinação Homóloga / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso / Proteína BRCA1 / Proteína BRCA2 / Reparo de DNA por Recombinação / Recombinação Homóloga / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2021 Tipo de documento: Article